MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5136
-0.0264
-4.89%
After Hours: 0.5136 0 0.00% 17:52 05/25 EDT
OPEN
0.5100
PREV CLOSE
0.5400
HIGH
0.5499
LOW
0.5022
VOLUME
55.26K
TURNOVER
0
52 WEEK HIGH
3.120
52 WEEK LOW
0.4500
MARKET CAP
18.13M
P/E (TTM)
-0.9355
1D
5D
1M
3M
1Y
5Y
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also comme...
GlobeNewswire · 5d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 05/18 12:17
Qualigen Therapeutics GAAP EPS of -$0.12 beats by $0.07, revenue of $0.72M misses by $0.14M
Qualigen Therapeutics press release (NASDAQ:QLGN): Q1 GAAP EPS of -$0.12 beats by $0.07. Revenue of $0.72M (-62.1% Y/Y) misses by $0.14M. As of March 31, 2022, Qualigen Therapeutics had $13.6
Seekingalpha · 05/13 11:50
BRIEF-Qualigen Therapeutics Provides Corporate Update, Reports First Quarter 2022 Financial Results
reuters.com · 05/13 11:38
Qualigen Therapeutics Q1 EPS $(0.12) Up From $(0.13) YoY, Sales $700.00K Down From $1.90M YoY
Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.12) per share. This is a 7.69 percent increase over losses of $(0.13) per share from the same period last year. The company reported $700.00 thousand
Benzinga · 05/13 10:06
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also comme...
GlobeNewswire · 05/13 10:00
Qualigen Therapeutics' Partner NanoSynex To Present Technology At BioMed Israel May 10-12
 Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing
Benzinga · 05/10 13:17
Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform
Benzinga · 05/03 18:24
More
No Data
Learn about the latest financial forecast of QLGN. Analyze the recent business situations of Qualigen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average QLGN stock price target is 7.25 with a high estimate of 8.00 and a low estimate of 6.50.
High8.00
Average7.25
Low6.50
Current 0.5136
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2020
Institutional Holdings
Institutions: 38
Institutional Holdings: 3.20M
% Owned: 9.07%
Shares Outstanding: 35.30M
TypeInstitutionsShares
Increased
5
85.52K
New
6
341.51K
Decreased
5
54.99K
Sold Out
5
233.93K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Poirier
President/Director
Amy Broidrick
Chief Financial Officer/Vice President - Finance
Christopher Lotz
Chief Operating Officer/Senior Vice President
Shishir Sinha
Senior Vice President
Tariq Arshad
Chief Scientific Officer/Vice President - Research & Development
Wajdi Abdul-Ahad
Director
Ira Ritter
Independent Director
Richard David
Independent Director
Sidney Emery
Independent Director
Matthew Korenberg
Independent Director
Kurt Kruger
No Data
No Data
About QLGN
Qualigen Therapeutics, Inc. is a biotechnology company that is focused on developing therapeutics for the treatment of cancer and infectious diseases. The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.